ArticleJournal of cardiac failure2016
Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure.
Article in Journal of cardiac failure, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- The Role of Oxidative Stress and Inflammatory Parameters in Heart Failure.Medicina (Kaunas, Lithuania) · 2024Pooled it
- NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial.Pharmacotherapy · 2021Trial
- Cardiac fibrosis: mechanistic insights and translational advances.Molecular biomedicine · 2026Review
- From acute diagnosis to longitudinal risk stratification: a paradigm shift in the clinical role of cardiac biomarkers.Frontiers in cardiovascular medicine · 2026Article
- Frailty and heart failure: State-of-the-art review.Journal of cachexia, sarcopenia and muscle · 2023Review
- Sarcopenia and Frailty in Heart Failure: Is There a Biomarker Signature?Current heart failure reports · 2022Review
- Circulating Procollagen Type III N-Terminal Peptide and Physical Function in Adults from the Long Life Family Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2021Article
- Myocardial fibrosis combined with NT-proBNP improves the accuracy of survival prediction in ADHF patients.BMC cardiovascular disorders · 2021Article
- Cox-sMBPLS: An Algorithm for Disease Survival Prediction and Multi-Omics Module Discovery IncorporatingFrontiers in genetics · 2021Article
- Beta-Blocker Dose Stratifies Mortality Risk in a Racially Diverse Heart Failure Population.Journal of cardiovascular pharmacology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundProcollagen type III N-terminal peptide (PIIINP) is a biomarker of cardiac fibrosis that is associated with heart failure prognosis in whites. Its prognostic significance in African Americans is unknown. We sought to determine whether PIIINP is associated with outcomes in African Americans with heart failure. METHODS AND
resultsBlood was collected from 138 African Americans with heart failure for determining PIIINP and genetic ancestry, and patients were followed prospectively for death or hospitalization for heart failure. PIIINP was inversely correlated with West African ancestry (R(2) = 0.061; P = .010). PIIINP > 4.88 ng/mL was associated with all-cause mortality on univariate (hazard ratio [HR] 4.9, 95% confidence interval [CI] 2.2-11.0; P < .001) and multivariate (HR 5.8; 95% CI 1.9-17.3; P = .002) analyses over a median follow-up period of 3 years. We also observed an increased risk for the combined outcome of all-cause mortality or hospitalization for heart failure with PIIINP > 4.88 ng/mL on univariate (HR 2.6, 95% CI 1.6-5.0; P < .001) and multivariate (HR 2.4, 95% CI 1.2-4.7; P = .016) analyses.
conclusionsHigh circulating PIIINP is associated with poor outcomes in African Americans with chronic heart failure, suggesting that PIIINP may be useful in identifying African Americans who may benefit from additional therapy to combat fibrosis as a means of improving prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.